MedKoo product information:

 Daunorubicin hydrochloride

daunorubicin hydrochloride is the hydrochloride salt of an anthracycline antineoplastic antibiotic with therapeutic effects similar to those of doxorubicin. Daunorubicin exhibits cytotoxic activity through topoisomerase-mediated interaction with DNA, thereby inhibiting DNA replication and repair and RNA and protein synthesis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

History

In the 1950s, an Italian research company, Farmitalia Research Laboratories, began an organized effort to isolate anticancer compounds from soil-based microbes. A soil sample was isolated from the area surrounding the Castel del Monte, a 13th century castle in Apulia. A new strain of Streptomyces peucetius which produced a red pigment was isolated, and an antibiotic was produced from this bacterium that was found to have good activity against murine tumors. Since a group of French researchers discovered the same compound at about the same time, the two teams named the compound daunorubicin, combining the name Dauni, a pre-Roman tribe that occupied the area of Italy where the compound was isolated, with the French word for ruby, rubis, describing the color. Clinical trials began in the 1960s, and the drug saw success in treating acute leukemia and lymphoma. However, by 1967, it was recognized that daunorubicin could produce fatal cardiac toxicity. From http://en.wikipedia.org/wiki/Daunorubicin.

DRUG DESCRIPTION

Cerubidine (daunorubicin hydrochloride) is the hydrochloride salt of an anthracycline cytotoxic antibiotic produced by a strain of Streptomyces coeruleorubidus. It is provided as a sterile reddish lyophilized powder in vials for intravenous administration only. Each vial contains 21.4 mg daunorubicin hydrochloride (equivalent to 20 mg of daunorubicin), and 100 mg mannitol. It is soluble in water when adequately agitated and produces a reddish solution. It has the following structural formula which may be described with the chemical name of (1S,3S)-3-Acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1-naphthacenyl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside hydrochloride. Its molecular formula is C27H29NO10•HCl with a molecular weight of 563.99. It is a hygroscopic crystalline powder. The pH of a 5 mg/mL aqueous solution is 4.5 to 6.5.

Mechanism of Action

Cerubidine has antimitotic and cytotoxic activity through a number of proposed mechanisms of action. Cerubidine forms complexes with DNA by intercalation between base pairs. It inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes. Single strand and double strand DNA breaks result.

Cerubidine may also inhibit polymerase activity, affect regulation of gene expression, and produce free radical damage to DNA.

Cerubidine possesses an antitumor effect against a wide spectrum of animal tumors, either grafted or spontaneous. 

 1: Li R, Wu R, Zhao L, Wu M, Yang L, Zou H. P-glycoprotein antibody functionalized carbon nanotube overcomes the multidrug resistance of human leukemia cells. ACS Nano. 2010 Mar 23;4(3):1399-408. PubMed PMID: 20148593.

2: Bisht S, Maitra A. Dextran-doxorubicin/chitosan nanoparticles for solid tumor therapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2009 Jul;1(4):415-25. Review. PubMed PMID: 20049807.

3: Matsumura Y, Kataoka K. Preclinical and clinical studies of anticancer agent-incorporating polymer micelles. Cancer Sci. 2009 Apr;100(4):572-9. Review. PubMed PMID: 19462526.

4: Hauswald S, Duque-Afonso J, Wagner MM, Schertl FM, Lübbert M, Peschel C, Keller U, Licht T. Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes. Clin Cancer Res. 2009 Jun 1;15(11):3705-15. Epub 2009 May 19. PubMed PMID: 19458058.

5: Lopez G, Liu J, Ren W, Wei W, Wang S, Lahat G, Zhu QS, Bornmann WG, McConkey DJ, Pollock RE, Lev DC. Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma. Clin Cancer Res. 2009 May 15;15(10):3472-83. Epub 2009 May 5. PubMed PMID: 19417021.

6: Olofsson MH, Cummings J, Fayad W, Brnjic S, Herrmann R, Berndtsson M, Hodgkinson C, Dean E, Odedra R, Wilkinson RW, Mundt KE, Busk M, Dive C, Linder S. Specific demonstration of drug-induced tumour cell apoptosis in human xenografts models using a plasma biomarker. Cancer Biomark. 2009;5(3):117-25. PubMed PMID: 19407366.

7: Simůnek T, Stérba M, Popelová O, Adamcová M, Hrdina R, Gersl V. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep. 2009 Jan-Feb;61(1):154-71. Review. PubMed PMID: 19307704.

8: Novotna R, Wsol V, Xiong G, Maser E. Inactivation of the anticancer drugs doxorubicin and oracin by aldo-keto reductase (AKR) 1C3. Toxicol Lett. 2008 Sep;181(1):1-6. Epub 2008 Jun 21. PubMed PMID: 18616992.

9: Lau D, Johl J, Huynh M, Davies A, Tanaka M, Lara P, Gandara D. Population-based phase I trial of irinotecan and epirubicin. Am J Clin Oncol. 2008 Jun;31(3):226-30. PubMed PMID: 18525299.

10: Ballatori E, Roila F, Ruggeri B, De Angelis V, Porzio G, Marchetti P; Italian Group for Antiemetic Research. Inappropriate doses of chemotherapy in Italian breast cancer patients enrolled in clinical trials. Tumori. 2007 Nov-Dec;93(6):540-3. PubMed PMID: 18338486.

11: Kouloulias VE, Koukourakis GV, Petridis AK, Kouvaris I, Gouliamos AD. The efficacy of caelyx and hyperthermia for anticancer treatment. Recent Pat Anticancer Drug Discov. 2007 Nov;2(3):246-50. Review. PubMed PMID: 18221068.

12: Herst PM, Petersen T, Jerram P, Baty J, Berridge MV. The antiproliferative effects of phenoxodiol are associated with inhibition of plasma membrane electron transport in tumour cell lines and primary immune cells. Biochem Pharmacol. 2007 Dec 3;74(11):1587-95. Epub 2007 Aug 19. PubMed PMID: 17904534.

13: Liang CH, Shiu LY, Chang LC, Sheu HM, Kuo KW. Solamargine upregulation of Fas, downregulation of HER2, and enhancement of cytotoxicity using epirubicin in NSCLC cells. Mol Nutr Food Res. 2007 Aug;51(8):999-1005. PubMed PMID: 17639997.

14: Sieghart W, Fuereder T, Schmid K, Cejka D, Werzowa J, Wrba F, Wang X, Gruber D, Rasoul-Rockenschaub S, Peck-Radosavljevic M, Wacheck V. Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation. Transplantation. 2007 Feb 27;83(4):425-32. PubMed PMID: 17318075.

15: Vogel C, Hager C, Bastians H. Mechanisms of mitotic cell death induced by chemotherapy-mediated G2 checkpoint abrogation. Cancer Res. 2007 Jan 1;67(1):339-45. PubMed PMID: 17210716.

16: Robert J. Preclinical assessment of anthracycline cardiotoxicity in laboratory animals: predictiveness and pitfalls. Cell Biol Toxicol. 2007 Jan;23(1):27-37. Epub 2006 Oct 13. Review. PubMed PMID: 17041747.

17: Menna P, Minotti G, Salvatorelli E. In vitro modeling of the structure-activity determinants of anthracycline cardiotoxicity. Cell Biol Toxicol. 2007 Jan;23(1):49-62. Epub 2006 Oct 9. Review. PubMed PMID: 17031515.

18: Mayer LD, Harasym TO, Tardi PG, Harasym NL, Shew CR, Johnstone SA, Ramsay EC, Bally MB, Janoff AS. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther. 2006 Jul;5(7):1854-63. PubMed PMID: 16891472.

19: Bridges EM, Bibby MC, Burchill SA. The hollow fiber assay for drug responsiveness in the Ewing's sarcoma family of tumors. J Pediatr. 2006 Jul;149(1):103-11. PubMed PMID: 16860137.

20: Hasinoff BB. Dexrazoxane use in the prevention of anthracycline extravasation injury. Future Oncol. 2006 Feb;2(1):15-20. Review. PubMed PMID: 16556068.

21: Saeki T, Tsuruo T, Sato W, Nishikawsa K. Drug resistance in chemotherapy for breast cancer. Cancer Chemother Pharmacol. 2005 Nov;56 Suppl 1:84-9. PubMed PMID: 16273361.

22: Glasmacher A, von Lilienfeld-Toal M. The current status of thalidomide in the management of multiple myeloma. Acta Haematol. 2005;114 Suppl 1:3-7. Review. PubMed PMID: 16166765.

23: Ozdemir FA, Anilanmert B, Pekin M. Spectrophotometric investigation of the chemical compatibility of the anticancer drugs irinotecan-HCl and epirubicin-HCl in the same infusion solution. Cancer Chemother Pharmacol. 2005 Nov;56(5):529-34. Epub 2005 Jun 10. PubMed PMID: 15947932.

24: Shanks RH, Rizzieri DA, Flowers JL, Colvin OM, Adams DJ. Preclinical evaluation of gemcitabine combination regimens for application in acute myeloid leukemia. Clin Cancer Res. 2005 Jun 1;11(11):4225-33. PubMed PMID: 15930361.

25: Gligorov J, Debourdeau P, Arsovski O, Lotz JP. [Cardiac prevention: the oncologic point of view]. Bull Cancer. 2004 Nov 1;91 Suppl 3:192-200. Review. French. PubMed PMID: 15899627.

26: Hofland KF, Thougaard AV, Sehested M, Jensen PB. Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin. Clin Cancer Res. 2005 May 15;11(10):3915-24. PubMed PMID: 15897593.

27: Zhu K, Gerbino E, Beaupre DM, Mackley PA, Muro-Cacho C, Beam C, Hamilton AD, Lichtenheld MG, Kerr WG, Dalton W, Alsina M, Sebti SM. Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells. Blood. 2005 Jun 15;105(12):4759-66. Epub 2005 Feb 22. PubMed PMID: 15728126; PubMed Central PMCID: PMC1895008.

28: Di Paolo A. Liposomal anticancer therapy: pharmacokinetic and clinical aspects. J Chemother. 2004 Nov;16 Suppl 4:90-3. Review. PubMed PMID: 15688620.

29: Chanan-Khan AA. Bcl-2 antisense therapy in multiple myeloma. Oncology (Williston Park). 2004 Nov;18(13 Suppl 10):21-4. Review. PubMed PMID: 15651173.

30: Ravindranath MH, Muthugounder S, Presser N, Viswanathan S. Anticancer therapeutic potential of soy isoflavone, genistein. Adv Exp Med Biol. 2004;546:121-65. Review. PubMed PMID: 15584372.

31: Pestalozzi BC, Knuth A. [New antibodies in cancer treatment]. Praxis (Bern 1994). 2004 Sep 22;93(39):1589-92. Review. German. PubMed PMID: 15500243.

32: Peer D, Dekel Y, Melikhov D, Margalit R. Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models. Cancer Res. 2004 Oct 15;64(20):7562-9. PubMed PMID: 15492283.

33: Yuan S, Zhang X, Lu L, Xu C, Yang W, Ding J. Anticancer activity of methoxymorpholinyl doxorubicin (PNU 152243) on human hepatocellular carcinoma. Anticancer Drugs. 2004 Jul;15(6):641-6. PubMed PMID: 15205610.

34: Ardavanis A, Tryfonopoulos D, Yiotis I, Gerasimidis G, Baziotis N, Rigatos G. Non-allergic nature of docetaxel-induced acute hypersensitivity reactions. Anticancer Drugs. 2004 Jul;15(6):581-5. PubMed PMID: 15205600.

35: Danson S, Ferry D, Alakhov V, Margison J, Kerr D, Jowle D, Brampton M, Halbert G, Ranson M. Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. Br J Cancer. 2004 Jun 1;90(11):2085-91. PubMed PMID: 15150584; PubMed Central PMCID: PMC2409484.

36: Wang S, Folkes A, Chuckowree I, Cockcroft X, Sohal S, Miller W, Milton J, Wren SP, Vicker N, Depledge P, Scott J, Smith L, Jones H, Mistry P, Faint R, Thompson D, Cocks S. Studies on pyrrolopyrimidines as selective inhibitors of multidrug-resistance-associated protein in multidrug resistance. J Med Chem. 2004 Mar 11;47(6):1329-38. PubMed PMID: 14998323.

37: Hu Y, Krishan A, Nie W, Sridhar KS, Mayer LD, Bally M. Synergistic cytotoxicity of pyrazoloacridine with doxorubicin, etoposide, and topotecan in drug-resistant tumor cells. Clin Cancer Res. 2004 Feb 1;10(3):1160-9. PubMed PMID: 14871996.

38: Vermorken JB. The role of anthracyclines in second-line therapy of ovarian cancer. Int J Gynecol Cancer. 2003 Nov-Dec;13 Suppl 2:178-84. Review. PubMed PMID: 14656277.

39: Cattel L, Ceruti M, Dosio F. From conventional to stealth liposomes: a new frontier in cancer chemotherapy. Tumori. 2003 May-Jun;89(3):237-49. Review. PubMed PMID: 12908776.

40: Peterson CM, Shiah JG, Sun Y, Kopecková P, Minko T, Straight RC, Kopecek J. HPMA copolymer delivery of chemotherapy and photodynamic therapy in ovarian cancer. Adv Exp Med Biol. 2003;519:101-23. Review. PubMed PMID: 12675211.

41: Sharpe M, Easthope SE, Keating GM, Lamb HM. Polyethylene glycol-liposomal doxorubicin: a review of its use in the management of solid and haematological malignancies and AIDS-related Kaposi's sarcoma. Drugs. 2002;62(14):2089-126. Review. PubMed PMID: 12269857.

42: Kabanov AV, Batrakova EV, Alakhov VY. Pluronic block copolymers for overcoming drug resistance in cancer. Adv Drug Deliv Rev. 2002 Sep 13;54(5):759-79. Review. PubMed PMID: 12204601.

43: Albella B, Faircloth G, López-Lázaro L, Guzmán C, Jimeno J, Bueren JA. In vitro toxicity of ET-743 and aplidine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors. comparison with the clinical results. Eur J Cancer. 2002 Jul;38(10):1395-404. PubMed PMID: 12091072.

44: Seymour LW, Ferry DR, Anderson D, Hesslewood S, Julyan PJ, Poyner R, Doran J, Young AM, Burtles S, Kerr DJ; Cancer Research Campaign Phase I/II Clinical Trials committee. Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J Clin Oncol. 2002 Mar 15;20(6):1668-76. PubMed PMID: 11896118.

45: Cutts SM, Rephaeli A, Nudelman A, Hmelnitsky I, Phillips DR. Molecular basis for the synergistic interaction of adriamycin with the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate (AN-9). Cancer Res. 2001 Nov 15;61(22):8194-202. PubMed PMID: 11719450.

46: Dowlati A, Haaga J, Remick SC, Spiro TP, Gerson SL, Liu L, Berger SJ, Berger NA, Willson JK. Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation. Clin Cancer Res. 2001 Oct;7(10):2971-6. PubMed PMID: 11595684.

47: Park JW, Kirpotin DB, Hong K, Shalaby R, Shao Y, Nielsen UB, Marks JD, Papahadjopoulos D, Benz CC. Tumor targeting using anti-her2 immunoliposomes. J Control Release. 2001 Jul 6;74(1-3):95-113. PubMed PMID: 11489487.

48: Matsuzaki A, Ishii E, Nagatoshi Y, Eguchi H, Koga H, Yanai F, Inada H, Nibu K, Tamai Y, Akiyoshi K, Nakayama H, Hara T, Take H, Miyazaki S, Okamura J. Long-term outcome of treatment with protocols AL841, AL851, and ALHR88 in children with acute lymphoblastic leukemia: results obtained by the Kyushu-Yamaguchi Children's Cancer Study Group. Int J Hematol. 2001 Apr;73(3):369-77. Review. PubMed PMID: 11345205.

49: Motoji T, Motomura S, Wang YH. Multidrug resistance of acute leukemia and a strategy to overcome it. Int J Hematol. 2000 Dec;72(4):418-24. Review. PubMed PMID: 11197207.

50: Dantzig AH, Law KL, Cao J, Starling JJ. Reversal of multidrug resistance by the P-glycoprotein modulator, LY335979, from the bench to the clinic. Curr Med Chem. 2001 Jan;8(1):39-50. Review. PubMed PMID: 11172691.

51: Zagozdzon R, Golab J. Immunomodulation by anticancer chemotherapy: more is not always better (review). Int J Oncol. 2001 Feb;18(2):417-24. Review. PubMed PMID: 11172612.

52: Bailly C, Goossens JF, Laine W, Anizon F, Prudhomme M, Ren J, Chaires JB. Formaldehyde-induced alkylation of a 2'-aminoglucose rebeccamycin derivative to both A.T and G.C base pairs in DNA. J Med Chem. 2000 Nov 30;43(24):4711-20. PubMed PMID: 11101362.

53: Baba H, Kohnoe S, Endo K, Ikeda Y, Toh Y, Nakashima H, Okamura T. [State of the treatment for gastrointestinal cancer]. Gan To Kagaku Ryoho. 2000 Jul;27(8):1233-46. Review. Japanese. PubMed PMID: 10945022.

54: Vadgama JV, Wu Y, Shen D, Hsia S, Block J. Effect of selenium in combination with Adriamycin or Taxol on several different cancer cells. Anticancer Res. 2000 May-Jun;20(3A):1391-414. PubMed PMID: 10928049.

55: Liao WC, Wu FY, Wu CW. Binary/ternary combined effects of vitamin K3 with other antitumor agents in nasopharyngeal carcinoma CG1 cells. Int J Oncol. 2000 Aug;17(2):323-8. PubMed PMID: 10891542.

56: Finlay GJ, Baguley BC. Effects of protein binding on the in vitro activity of antitumour acridine derivatives and related anticancer drugs. Cancer Chemother Pharmacol. 2000;45(5):417-22. PubMed PMID: 10803926.

57: Hafkemeyer P, Licht T, Pastan I, Gottesman MM. Chemoprotection of hematopoietic cells by a mutant P-glycoprotein resistant to a potent chemosensitizer of multidrug-resistant cancers. Hum Gene Ther. 2000 Mar 1;11(4):555-65. Erratum in: Hum Gene Ther 2000 May 1;11(7):1112. PubMed PMID: 10724034.

58: Supko JG, Nair RV, Seiden MV, Lu H. Adaptation of solid phase extraction to an automated column switching method for online sample cleanup as the basis of a facile and sensitive high-performance liquid chromatographic assay for paclitaxel in human plasma. J Pharm Biomed Anal. 1999 Dec;21(5):1025-36. PubMed PMID: 10703971.

59: Armand JP, Seymour L, Evans TR. Raltitrexed (Tomudex) in combination with platinum-based agents and/or anthracyclines: preliminary results of phase I clinical trials. Eur J Cancer. 1999 Mar;35 Suppl 1:S14-8. PubMed PMID: 10645209.

60: Licht T, Aran JM, Goldenberg SK, Vieira WD, Gottesman MM, Pastan I. Retroviral transfer of human MDR1 gene to hematopoietic cells: effects of drug selection and of transcript splicing on expression of encoded P-glycoprotein. Hum Gene Ther. 1999 Sep 1;10(13):2173-85. PubMed PMID: 10498249.

61: Hooijberg JH, Broxterman HJ, Scheffer GL, Vrasdonk C, Heijn M, de Jong MC, Scheper RJ, Lankelma J, Pinedo HM. Potent interaction of flavopiridol with MRP1. Br J Cancer. 1999 Sep;81(2):269-76. PubMed PMID: 10496352; PubMed Central PMCID: PMC2362861.

62: Robert J. Multidrug resistance in oncology: diagnostic and therapeutic approaches. Eur J Clin Invest. 1999 Jun;29(6):536-45. Review. PubMed PMID: 10354216.

63: Garner AP, Paine MJ, Rodriguez-Crespo I, Chinje EC, Ortiz De Montellano P, Stratford IJ, Tew DG, Wolf CR. Nitric oxide synthases catalyze the activation of redox cycling and bioreductive anticancer agents. Cancer Res. 1999 Apr 15;59(8):1929-34. PubMed PMID: 10213502.

64: Andoh T. Bis(2,6-dioxopiperazines), catalytic inhibitors of DNA topoisomerase II, as molecular probes, cardioprotectors and antitumor drugs. Biochimie. 1998 Mar;80(3):235-46. Review. PubMed PMID: 9615863.

65: Arcamone F, Animati F, Capranico G, Lombardi P, Pratesi G, Manzini S, Supino R, Zunino F. New developments in antitumor anthracyclines. Pharmacol Ther. 1997 Oct-Dec;76(1-3):117-24. Review. PubMed PMID: 9535173.

66: Duncan R, Coatsworth JK, Burtles S. Preclinical toxicology of a novel polymeric antitumour agent: HPMA copolymer-doxorubicin (PK1). Hum Exp Toxicol. 1998 Feb;17(2):93-104. PubMed PMID: 9506260.

67: Tsuchida S, Kimura J, Hayakari M, Ishikawa T. [Usefulness of glutathione S-transferase as a tumor marker]. Rinsho Byori. 1997 Dec;45(12):1125-32. Review. Japanese. PubMed PMID: 9437892.

68: Singal PK, Iliskovic N, Li T, Kumar D. Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB J. 1997 Oct;11(12):931-6. Review. PubMed PMID: 9337145.

69: Bosch I, Crankshaw CL, Piwnica-Worms D, Croop JM. Characterization of functional assays of multidrug resistance P-glycoprotein transport activity. Leukemia. 1997 Jul;11(7):1131-7. PubMed PMID: 9205002.

70: Watanabe T, Iwasaki M, Todaka T, Morikawa H, Ohtawa M. Effect of SDZ PSC 833 ([3'-keto-Bmt1]-[Val2]-cyclosporin) on serum protein binding and distribution to blood cells of doxorubicin, vincristine and etoposide in vitro. Anticancer Drugs. 1997 Apr;8(4):400-4. PubMed PMID: 9180396.

71: Sikic BI, Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L, Chen G. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol. 1997;40 Suppl:S13-9. Review. PubMed PMID: 9272128.

72: Zervas K, Pouli A, Perifanis V, Papanastasiou K, Chatziyianni M, Mitsouli C, Maniatis A. Maintenance therapy with interferon-alpha (IFN-alpha) versus IFN-alpha plus chemotherapy in multiple myeloma (MM). The Greek Myeloma Study Group. Eur J Haematol. 1996 Aug;57(2):142-8. PubMed PMID: 8856091.

73: Hellmann K. Cardioprotection by dexrazoxane (Cardioxane; ICRF 187): progress in supportive care. Support Care Cancer. 1996 Jul;4(4):305-7. Review. PubMed PMID: 8829310.

74: Bissery MC, Vrignaud P, Lavelle F, Chabot GG. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. Anticancer Drugs. 1996 Jun;7(4):437-60. PubMed PMID: 8826613.

75: Berger I, Su L, Spitzner JR, Kang C, Burke TG, Rich A. Molecular structure of the halogenated anti-cancer drug iododoxorubicin complexed with d(TGTACA) and d(CGATCG). Nucleic Acids Res. 1995 Nov 11;23(21):4488-94. PubMed PMID: 7501474; PubMed Central PMCID: PMC307408.

76: Ito H. [Experimental study and clinical application of a new combination chemotherapy with cis-platinum, adriamycin and carboquone in patients with advanced prostate cancer]. Nippon Ika Daigaku Zasshi. 1995 Oct;62(5):456-68. Japanese. PubMed PMID: 7499463.

77: Depenbrock H, Wenger M, Peter R, Fellbaum C, Block T, Rastetter J, Hanauske AR. Investigation of the comparative effects of 2-chlorodeoxyadenosine on tumor colony forming units in vitro. Invest New Drugs. 1995;13(2):117-23. PubMed PMID: 8617573.

78: Izumi R, Shimizu K, Iyobe T, Ii T, Yagi M, Matsui O, Nonomura A, Miyazaki I. Postoperative adjuvant hepatic arterial infusion of Lipiodol containing anticancer drugs in patients with hepatocellular carcinoma. Hepatology. 1994 Aug;20(2):295-301. PubMed PMID: 8045490.

79: Lasota WS, de Valeriola DL, Piccart MJ. Potential role of oral anthracyclines in older patients with cancer. Drugs Aging. 1994 May;4(5):392-402. Review. PubMed PMID: 8043941.

80: Kirshenbaum MR, Chen SF, Behrens CH, Papp LM, Stafford MM, Sun JH, Behrens DL, Fredericks JR, Polkus ST, Sipple P, et al. (R,R)-2,2'-[1,2-ethanediylbis[imino(1-methyl-2,1-ethanediyl)]]- bis[5-nitro-1H-benz[de]isoquinoline-1,3-(2H)-dione] dimethanesulfonate (DMP 840), a novel bis-naphthalimide with potent nonselective tumoricidal activity in vitro. Cancer Res. 1994 Apr 15;54(8):2199-206. PubMed PMID: 8174127.

81: Robert J. Epirubicin. Clinical pharmacology and dose-effect relationship. Drugs. 1993;45 Suppl 2:20-30. Review. PubMed PMID: 7693418.

82: Weiss RB. The anthracyclines: will we ever find a better doxorubicin? Semin Oncol. 1992 Dec;19(6):670-86. Review. PubMed PMID: 1462166.

83: Matsumoto J, Minami T, Sato T, Onodera T. [A clinical trial of arterial infusion chemotherapy combined with calcium antagonist for liver metastases]. Gan To Kagaku Ryoho. 1992 Aug;19(10 Suppl):1553-6. Japanese. PubMed PMID: 1530306.

84: Ettinger DS, Finkelstein DM, Abeloff MD, Skeel RT, Stott PB, Frontiera MS, Bonomi PD. Justification for evaluating new anticancer drugs in selected untreated patients with extensive-stage small-cell lung cancer: an Eastern Cooperative Oncology Group randomized study. J Natl Cancer Inst. 1992 Jul 15;84(14):1077-84. PubMed PMID: 1320131.

85: Okada S, Okazaki N, Nose H, Yoshimori M, Aoki K. Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy. Hepatology. 1992 Jul;16(1):112-7. PubMed PMID: 1377657.

86: Perno CF, Yarchoan R, Balzarini J, Bergamini A, Milanese G, Pauwels R, De Clercq E, Rocchi G, Calio R. Different pattern of activity of inhibitors of the human immunodeficiency virus in lymphocytes and monocyte/macrophages. Antiviral Res. 1992 Apr;17(4):289-304. PubMed PMID: 1322645.

87: Herait P, Poutignat N, Marty M, Bugat R. Early assessment of a new anticancer drug analogue--are the historical comparisons obsolete? The French experience with pirarubicin. Eur J Cancer. 1992;28A(10):1670-6. PubMed PMID: 1389483.

88: Alexander RB. Tumor necrosis factor and chemotherapeutic drugs targeted at DNA topoisomerase II for the treatment of genitourinary malignancies. Cancer Treat Res. 1992;59:105-20. Review. PubMed PMID: 1347688.

89: Okada S, Okazaki N. [Chemotherapy in cancers of the gallbladder and bile ducts]. Gan To Kagaku Ryoho. 1991 Jul;18(8):1269-72. Japanese. PubMed PMID: 2069397.

90: Okamoto H, Saijo N. [Preclinical trials from the standpoint of clinical trials]. Gan To Kagaku Ryoho. 1991 Jul;18(9):1467-75. Japanese. PubMed PMID: 1854217.

91: Mickisch GH, Merlino GT, Galski H, Gottesman MM, Pastan I. Transgenic mice that express the human multidrug-resistance gene in bone marrow enable a rapid identification of agents that reverse drug resistance. Proc Natl Acad Sci U S A. 1991 Jan 15;88(2):547-51. PubMed PMID: 1671173; PubMed Central PMCID: PMC50848.

92: Hazama S, Oka M, Shimizu R, Yano K, Yoshino S, Iizuka N, Murakami T, Suzuki T. [Intraarterial combination immunotherapy in hepatocellular carcinoma]. Gan To Kagaku Ryoho. 1990 Aug;17(8 Pt 2):1638-42. Japanese. PubMed PMID: 2167639.

93: Wierzba K, Sugimoto Y, Matsuo K, Toko T, Takeda S, Yamada Y, Tsukagoshi S. Menogaril, an anthracycline compound with a novel mechanism of action: cellular pharmacology. Jpn J Cancer Res. 1990 Aug;81(8):842-9. PubMed PMID: 2144516.

94: Gianni L, Viganò L, Surbone A, Ballinari D, Casali P, Tarella C, Collins JM, Bonadonna G. Pharmacology and clinical toxicity of 4'-iodo-4'-deoxydoxorubicin: an example of successful application of pharmacokinetics to dose escalation in phase I trials. J Natl Cancer Inst. 1990 Mar 21;82(6):469-77. PubMed PMID: 2313718.

95: Yamaguchi T, Takahashi T, Yokota T, Kitamura K, Noguchi A, Doi M, Chimori Y, Honda M, Noguchi A, Otsuji E, et al. [Host factors that changes the distribution of immunotoxin]. Gan To Kagaku Ryoho. 1990 Mar;17(3 Pt 2):570-4. Review. Japanese. PubMed PMID: 2138873.

96: Saito R, Tsuchiya S, Ishizuka T, Fueki N, Ezawa K, Minato K, Nakano H, Takise A, Kurihara M, Fueki R. Clinical effects of cepharanthin (Ceph.) on leukopenia by chemotherapy in lung cancer patients. Nippon Gan Chiryo Gakkai Shi. 1989 Dec 20;24(11):2587-93. PubMed PMID: 2559129.

97: Sothern RB, Lévi F, Haus E, Halberg F, Hrushesky WJ. Control of a murine plasmacytoma with doxorubicin-cisplatin: dependence on circadian stage of treatment. J Natl Cancer Inst. 1989 Jan 18;81(2):135-45. PubMed PMID: 2909754.

98: Noguchi S, Miyauchi K, Nishizawa Y, Sasaki Y, Imaoka S, Iwanaga T, Koyama H, Terasawa T. Augmentation of anticancer effect with angiotensin II in intraarterial infusion chemotherapy for breast carcinoma. Cancer. 1988 Aug 1;62(3):467-73. PubMed PMID: 3292035.

99: Saeki T, Jinushi K, Kodama H, Yoshinaka K, Toge T, Niimoto M, Hattori T. [Fundamental and clinical studies of intra-arterial chemotherapy combined with degradable starch microspheres (DSM)]. Gan To Kagaku Ryoho. 1988 Aug;15(8 Pt 2):2633-9. Japanese. PubMed PMID: 3137886.

100: Tsukagoshi S. [Problems in the development of analogs of anticancer drugs]. Gan To Kagaku Ryoho. 1988 Aug;15(8):2173-8. Japanese. PubMed PMID: 2457354.

101: Speth PA, van Hoesel QG, Haanen C. Clinical pharmacokinetics of doxorubicin. Clin Pharmacokinet. 1988 Jul;15(1):15-31. Review. PubMed PMID: 3042244.

102: Boven E, Winograd B, Fodstad O, Lobbezoo MW, Pinedo HM. Preclinical phase II studies in human tumor lines: a European multicenter study. Eur J Cancer Clin Oncol. 1988 Mar;24(3):567-73. PubMed PMID: 3383962.

103: Sternberg CN, Sordillo PP, Cheng E, Chuang YJ, Niedzwiecki D. Evaluation of new anticancer agents against human pancreatic carcinomas in nude mice. Am J Clin Oncol. 1987 Jun;10(3):219-21. PubMed PMID: 2884864.

104: Riggs CE Jr, Sharp SA. Adriamycin: review of clinical pharmacology and toxicity of an effective anticancer drug. Iowa Med. 1987 May;77(5):242, 245-51. PubMed PMID: 3298138.

105: Nishiyama M, Nosoh Y, Yamaguchi M, Hirabayashi N, Toge T, Niimoto M, Hattori T. Comparative study on nude mice isotope assay (NM-IA) and subrenal capsule assay (SRCA) sensitivity tests of anticancer agents. Jpn J Surg. 1987 Mar;17(2):99-103. PubMed PMID: 3114529.

106: Robert J. Continuous infusion or intravenous bolus: what is the rationale for doxorubicin administration? Cancer Drug Deliv. 1987;4(3):191-9. Review. PubMed PMID: 3329957.

107: Wadler S, Fuks JZ, Wiernik PH. Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds. J Clin Pharmacol. 1986 Sep-Oct;26(7):491-509. Review. PubMed PMID: 2944917.

108: Hagiwara A, Ahn T, Ueda T, Iwamoto A, Ueda T, Torii T, Takahashi T. Anticancer agents adsorbed by activated carbon particles, a new form of dosage enhancing efficacy on lymphnodal metastases. Anticancer Res. 1986 Sep-Oct;6(5):1005-8. PubMed PMID: 2432828.

109: Collins JM, Zaharko DS, Dedrick RL, Chabner BA. Potential roles for preclinical pharmacology in phase I clinical trials. Cancer Treat Rep. 1986 Jan;70(1):73-80. PubMed PMID: 3753662.

110: Hurteloup P, Ganzina F. Clinical studies with new anthracyclines: epirubicin, idarubicin, esorubicin. Drugs Exp Clin Res. 1986;12(1-3):233-46. Review. PubMed PMID: 3525075.

111: Romanini A, Febi G, Danesi R, Del Tacca M. [Recent pharmacotoxicologic and clinical findings on adriamycin]. Minerva Med. 1985 Oct 20;76(40):1863-76. Review. Italian. PubMed PMID: 2997664.

112: Hrushesky WJ. Circadian timing of cancer chemotherapy. Science. 1985 Apr 5;228(4695):73-5. PubMed PMID: 3883493.

113: Yoshimori M, Tajiri H, Nakamura K, Ozaki H. [Chemotherapy of pancreatic cancer]. Gan To Kagaku Ryoho. 1985 Feb;12(2):227-34. Japanese. PubMed PMID: 3155930.

114: Schlag P, Flentje D. Chemosensitivity testing of human neoplasms using the soft agar colony assay. Cancer Treat Rev. 1984 Mar;11 Suppl A:131-7. PubMed PMID: 6733715.

115: Reich SD. Rationale for anticancer drug dosing schedules. Cancer Nurs. 1983 Dec;6(6):465-7. PubMed PMID: 6360342.

116: Carlson RW, Sikic BI. Continuous infusion or bolus injection in cancer chemotherapy. Ann Intern Med. 1983 Dec;99(6):823-33. Review. PubMed PMID: 6197002.

117: Schabel FM Jr, Skipper HE, Trader MW, Laster WR Jr, Griswold DP Jr, Corbett TH. Establishment of cross-resistance profiles for new agents. Cancer Treat Rep. 1983 Oct;67(10):905-22. Review. PubMed PMID: 6354439.

118: Garattini S. Is it necessary to measure plasma levels of anticancer drugs? Biomed Pharmacother. 1983;37(5):209-10. PubMed PMID: 6661506.

119: Neidhart JA, Gagen M, Young D, Wilson HE. Specific antiemetics for specific cancer chemotherapeutic agents: haloperidol versus benzquinamide. Cancer. 1981 Mar 15;47(6):1439-43. PubMed PMID: 7013968.

120: Zimmerman SE, Smith FP, Schein PS. Chemotherapy of pancreatic carcinoma. Cancer. 1981 Mar 15;47(6 Suppl):1724-8. PubMed PMID: 6456058.

121: Chauvergne J, Durand M, Berlie J. [The chemotherapy of advanced breast cancer. A report on the first 600 cases in a cooperative programme to carry out a systematic study (1974-1977) (author's transl)]. J Gynecol Obstet Biol Reprod (Paris). 1978 May-Jun;7(4):877-86. French. PubMed PMID: 361799.

122: Weiss AJ, Manthel RW. Experience with the use of adriamycin in combination with other anticancer agents using a weekly schedule, with particular reference to lack of cardiac toxicity. Cancer. 1977 Nov;40(5):2046-52. PubMed PMID: 336177.